

Date: December 20, 2025

To,
Sr. General Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

BSE Scrip Code: 544319

To,
Sr. General Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

NSE Symbol: SENORES

Sub.: Intimation under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

With reference to the captioned subject, and the earlier intimation given by the Company on December 15, 2025 regarding execution of a Share Purchase Agreement dated December 15, 2025 between the Company and Apnar Pharma Private Limited ("Apnar"), we wish to inform that as per the approval accorded by the Management Committee of the Board of Directors of the Company, in its meeting held on December 15, 2025 the Company has entered into a Loan Agreement dated December 20, 2025 with Apnar for granting inter-corporate loan of an amount upto ₹ 15,00,00,000/- (Rupees Fifteen Crores Only), in one or more tranches.

The details as required under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the SEBI Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 are enclosed herewith as **Annexure-A**.

This is for your information and records. The same is also being uploaded on the website of the Company at www.senorespharma.com.

Thanking you.

For Senores Pharmaceuticals Limited

Vinay Kumar Mishra
Company Secretary and Compliance Officer
ICSI Membership No.: F11464

Encl.: As mentioned above

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com

W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263

Annexure – A
Disclosure under Regulation 30(6) read with Para A (1) of Part A of Schedule III of the Listing Regulations and the SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024
Acquisition (including agreement to acquire):

Sr. No.	Particulars	Description
1.	Name(s) of parties with whom the agreement is entered	Apnar Pharma Private Limited (" Apnar " / " Borrower ").
2.	Purpose of entering into the agreement	Inter Corporate Loan
3.	Size of agreement	₹ 15,00,00,000/- (Rupees Fifteen Crores Only)
4.	Shareholding, if any, in the entity with whom the agreement is executed	Nil
5.	Significant terms of the agreement (in brief) special rights like right to appoint directors, first right to share subscription in case of issuance of shares, right to restrict any change in capital structure etc.	Interest Rate: Interest shall be on arm's length basis at the rate of 10% per annum on the outstanding loan amount Tenure: Loan is re-payable on demand Purpose: Loan disbursed shall be utilized by Apnar for discharging and/or paying off its liabilities as mentioned in the Share Purchase Agreement ("SPA") dated December 15, 2025.
6.	Whether, the said parties are related to promoter/promoter group/ group companies in any manner. If yes, nature of relationship	As on the date of the loan agreement i.e. December 20, 2025 the parties are not related to each other.
7.	Whether the transaction would fall within related party transactions? If yes, whether the same is done at "arm's length"	Not applicable
8.	In case of issuance of shares to the parties, details of issue price, class of shares issued	Not applicable
9.	In case of loan agreements, details of lender/borrower, nature of the loan, total amount of loan granted/taken, total amount outstanding, date of execution of the loan agreement/sanction letter, details of the security provided to the lenders / by the borrowers for such loan or in case outstanding loans lent to a party or borrowed from a party become material on a cumulative basis	Lender: Senores Pharmaceuticals Limited Borrower: Apnar Pharma Private Limited Nature of loan: Unsecured Inter-corporate Loan Amount of loan: ₹ 15,00,00,000/- (Rupees Fifteen Crores Only) Date of execution of Loan Agreement: December 20, 2025 Security provided, if any: Nil

Senores Pharmaceuticals Limited

 1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
 Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

 P: +91 79 2999 9857 | E: info@senorespharma.com

 W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263

Sr. No.	Particulars	Description
		Total amount of loan outstanding as on date of disclosure: ₹ 1,00,00,000/- (Rupees One Crore Only). Other terms: Apnar shall repay the loan in one or more tranches upon demand by Senores. All outstanding amounts shall immediately become due and payable upon such demand. Apnar has the flexibility to pre-pay the loan amount, if mutually agreed between the parties.
10.	Any other disclosures related to such agreements, viz., details of nominee on the board of directors of the listed entity, potential conflict of interest arising out of such agreements, etc.	Not applicable
11.	In case of rescission, amendment or alteration, listed entity shall disclose additional details to the stock exchange(s): i. name of parties to the agreement; ii. nature of the agreement; iii. date of execution of the agreement; iv. details of amendment and impact thereof or reasons of termination and impact thereof	Not applicable

** The said amount of ₹ 1,00,00,000/- (Rupees One Crore Only) is out of earlier granted loan of ₹ 1,50,00,000/- (Rupees One Crore Fifty Lakhs Only). Since, the same was not material as per Regulation 30(4) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, it was not reported/ disclosed to Stock Exchange.*

Senores Pharmaceuticals Limited

1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park,
 Ambali Bopal Road, Ahmedabad-380054, Gujarat, India

P: +91 79 2999 9857 | E: info@senorespharma.com

W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263